Site updated at Wednesday, 22 June 2016

Living with Dementia


Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment

Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes… Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment   

FDA OKs Agent to Differentiate Alzheimer’s

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD,… FDA OKs Agent to Differentiate Alzheimer’s   


microhemmorhage1 - cognitive decline19 - diagnosis of dementia1 - memory capacity1 - parkinson's drug2 - saykin1 - angina1 - parkinsonian brain1 - gradual degeneration1 - induced pluripotent stem cells1 - high oestrogen levels1 - late-onset alzheimer's2 - alzheimer drug1 - dementia praecox1 - amyloid-beta protein1 - memory losses1 - alcohol consumption1 - alzheimer's-like tau tangles1 - psychotic symptoms1 - amyloidosis1 - korsakoff syndrome3 - oxidative stress1 - antihypertensive drugs1 - reverse cholesterol transport1 - aids related dementia1 - emotional symptoms1 - arteriosclerotic dementia1 - brain changes1 - social engagement1 - alzheimer's brain1 -